White Paper

Eight Must-Know Considerations About Rare, Dermatologic Trials For Children

Source: Synteract
patient-doctor-hands

Did you know that 80% of rare diseases impact children – and many of these are in the dermatological therapeutic area? Sadly, several rare, dermatological conditions impact children who may never live to adulthood without early intervention. In delaying treatment, these pediatric patients cannot always recover the loss of function if the skin cells die. So, not only is it important for drug developers working on new treatments for dermatologic diseases that affect children to include them in the clinical trials for new drugs, it is now mandated by the FDA. However, including children presents its own set of operational challenges.

Dermatology trials are somewhat unique, and even more so with children included in the trial. Let’s discuss some of the key considerations that should be taken into account when planning rare, dermatologic trials for children.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: